Search results with tag "Haemato"
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukLCA Haemato-Oncology Clinical Guidelines Plasma Cell Disorders April 2015
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukLCA Haemato-Oncology Clinical Guidelines Lymphoid Malignancies . Part 1: Hodgkin Lymphoma . August 2015
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukLCA HAEMATO-ONCOLOGY CLINICAL GUIDELINES 6 2. Clinical Features 2.1. Essential thrombocythaemia (ET) ET is characterised by a persistent thrombocytosis.
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukLCA Haemato-Oncology Clinical Guidelines Acute Leukaemia s and Myeloid Neoplasms. Part 1: Acute Lymphoblastic Leukaemia . April 2015
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukIn western countries diffuse large B cell lymphoma (DLBCL) constitutes 25–30% of adult non-Hodgkin’s lymphoma (NHL) and is the most common subtype of NHL.
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukAll patients where a new line of therapy needs to be considered. All patients with a re-staging assessment of response to treatment. All patients in whom an allogeneic stem cell transplant is a consideration.